Previous 10 | Next 10 |
2023-11-15 10:12:31 ET More on Madrigal, Newmont, etc. Madrigal Pharmaceuticals: Preparing For Resmetirom's Commercialization In 2024 Madrigal Pharmaceuticals Bolstered By $500 Million Equity Infusion Is A 'Buy' Into 2024 Newmont: Margins Improve, But Production Belo...
Data to be featured in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting® Analyses from comprehensive set of noninvasive tests used in MAESTRO-NASH provide new insights on strategies to identify patients and measure response to res...
CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer. ...
2023-11-09 13:01:38 ET Summary Madrigal Pharmaceuticals is more than 100% higher than a year ago, though the stock has been grinding constantly lower from it's high-water mark in late-April, sitting some 55% below that level. The company completed a $500 million stock offering to ...
2023-11-07 01:11:15 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals Bolstered By $500 Million Equity Infusion Is A 'Buy' Into 2024 Madrigal's Resmetirom Nears Commercialization Despite Market Concerns Madrigal Pharmaceuticals: The NASH Market Is No Longe...
Priority Review of resmetirom new drug application underway in the U.S. Bill Sibold appointed Chief Executive Officer of Madrigal in September 2023 $500 million financing provides Madrigal with funds to support a potential first-to-market launch of resmetirom in the U.S. ...
2023-11-05 03:19:13 ET Summary Madrigal Pharmaceuticals is transitioning from clinical trials to market-ready solutions for non-alcoholic steatohepatitis (NASH) and liver fibrosis. Their leading candidate, Resmetirom, is in Phase III clinical trials and is expected to enter the ma...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Madrigal Pharmaceuticals Inc. (MDGL) is expected to report $-4.78 for Q3 2023
2023-10-26 01:30:02 ET Summary 89bio shows promise in NASH therapeutics, backed by robust Phase 2b trials of its drug pegozafermin. Financially stable with a significant cash runway, but a sharp YoY increase in operating expenses without a partnership to offset some costs is a con...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...